Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2013 2
2014 1
2017 1
2020 3
2021 3
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.
Daly MB, Pal T, Maxwell KN, Churpek J, Kohlmann W, AlHilli Z, Arun B, Buys SS, Cheng H, Domchek SM, Friedman S, Giri V, Goggins M, Hagemann A, Hendrix A, Hutton ML, Karlan BY, Kassem N, Khan S, Khoury K, Kurian AW, Laronga C, Mak JS, Mansour J, McDonnell K, Menendez CS, Merajver SD, Norquist BS, Offit K, Rash D, Reiser G, Senter-Jamieson L, Shannon KM, Visvanathan K, Welborn J, Wick MJ, Wood M, Yurgelun MB, Dwyer MA, Darlow SD. Daly MB, et al. Among authors: kassem n. J Natl Compr Canc Netw. 2023 Oct;21(10):1000-1010. doi: 10.6004/jnccn.2023.0051. J Natl Compr Canc Netw. 2023. PMID: 37856201
Reply to K. Nozawa et al.
Schneider BP, Ballinger TJ, Jiang G, Shen F, Kassem N, Miller KD. Schneider BP, et al. Among authors: kassem n. J Clin Oncol. 2022 Jun 10;40(17):1963-1964. doi: 10.1200/JCO.22.00288. Epub 2022 Mar 31. J Clin Oncol. 2022. PMID: 35357884 No abstract available.
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
Schneider BP, Jiang G, Ballinger TJ, Shen F, Chitambar C, Nanda R, Falkson C, Lynce FC, Gallagher C, Isaacs C, Blaya M, Paplomata E, Walling R, Daily K, Mahtani R, Thompson MA, Graham R, Cooper ME, Pavlick DC, Albacker LA, Gregg J, Solzak JP, Chen YH, Bales CL, Cantor E, Hancock BA, Kassem N, Helft P, O'Neil B, Storniolo AMV, Badve S, Miller KD, Radovich M. Schneider BP, et al. Among authors: kassem n. J Clin Oncol. 2022 Feb 1;40(4):345-355. doi: 10.1200/JCO.21.01657. Epub 2021 Dec 15. J Clin Oncol. 2022. PMID: 34910554 Clinical Trial.
Discerning the clinical relevance of biomarkers in early stage breast cancer.
Ballinger TJ, Kassem N, Shen F, Jiang G, Smith ML, Railey E, Howell J, White CB, Schneider BP. Ballinger TJ, et al. Among authors: kassem n. Breast Cancer Res Treat. 2017 Jul;164(1):89-97. doi: 10.1007/s10549-017-4238-0. Epub 2017 Apr 11. Breast Cancer Res Treat. 2017. PMID: 28401365 Free article.
14 results